Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.

European journal of clinical pharmacology - 1 Apr 2012

Afsar Nasir Ali, Ufer Mike, Haenisch Sierk, Remmler Cornelia, Mateen Ahmed, Usman Ahmed, Ahmed Khwaja Zafar, Ahmad Hakimuddin Razi, Cascorbi Ingolf

Abstract excerpt

PURPOSE: The cytotoxic drug cyclophosphamide (CP) is bioactivated into 4-hydroxy-cyclophosphamide (4-OH-CP) through cytochrome P450 enzymes and cleared through aldehyde dehydrogenase and glutathione S-transferase. This prospective study analyzes the influence of drug metabolizing enzyme genotype on (1) plasma 4-OH-CP:CP ratio and (2) myelotoxicity in breast cancer patients on 500 mg/m(2) cyclophosphamide....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aldehyde Dehydrogenase
Share to Antineoplastic Agents, Alkylating

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Cytochrome P-450 Enzyme System

Share to Doxorubicin

Share to Fluorouracil

Share to Glutathione Transferase

Share to Leukocyte Count

Source

Identifiers

PMID: 22012257
DOI: 10.1007/s00228-011-1134-0

Genes

GSTA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relationship of drug metabolizing enzyme genotype to plasma levels as well as myelotoxicity of cyclophosphamide in breast cancer patients.PMID 22012257Read ↗

Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy.Semantic proximity Read ↗

Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.Semantic proximity Read ↗

Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.Semantic proximity Read ↗

Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.Semantic proximity Read ↗

Association of ALDH1A1 Polymorphism With Toxicity From Cyclophosphamide TreatmentSemantic proximity Read ↗

Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.Semantic proximity Read ↗

Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.Semantic proximity Read ↗

Myelosuppression in a Metastatic Breast Cancer Patient with GSTP1 rs1695 Mutation Induced by Adriamycin and CyclophosphamideSemantic proximity Read ↗

Pharmacogenetics as a Future Tool to Risk-Stratify Breast Cancer Patients According to Chemotoxicity Potential from the Doxorubicin Hydrochloride and Cyclophosphamide (AC) RegimenSemantic proximity Read ↗

Gene Polymorphisms in Cyclophosphamide Metabolism Pathway,Treatment-Related Toxicity, and Disease-Free Survival in SWOG 8897 Clinical Trial for Breast CancerSemantic proximity Read ↗

The Effect of CYP2C19*2 (rs4244285) and CYP17 (rs743572) SNPs on Adriamycin and Paclitaxel based Chemotherapy Outcomes in Breast Cancer Patients.Semantic proximity Read ↗

Genotype frequencies of selected drug metabolizing enzymes and ABC drug transporters among breast cancer patients on FAC chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.